🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Did you ever wonder why our marrow is located inside of our *bones*, #MedTwitter? There’s no a priori anatomical reason it should be sited there. Blood cells could form in our spleens & livers, as they do during our fetal lives; or elsewhere, as in some animals. Let’s discuss! /1

Such an interesting story, thanks for sharing!

The remarkable story of Velcade. In the year 2000, a few of us attended an angiogenesis meeting in Boston. We were there to discuss thalidomide But a side meeting that evening led to trial that went on to get Velcade FDA approved for myeloma. NEJM Story in thread.

The most impressive myeloma abstract at #ASCO25 Outstanding longterm efficacy with cilta-cel CAR-T. 5 year survival rate 50% 5 year PFS rate of 33% Astounding given multi-drug relapsed refractory setting. Plasma Cell Pete Noopur Raje Tom Martin Yi Lin Deepu Madduri

Ultimate review on Myeloma bone disease! Open access too doi.org/10.1016/j.blre… #mmsm Vincent Rajkumar Rahul Banerjee, MD, FACP @urvishahMD Ben Derman Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Luciano J Costa Robert Z. Orlowski Shaji Kumar Anup Joseph Devasia

🧵 Top 10 ASCO 2025 Myeloma Abstracts – A Thread Here’s what stands out from this year’s abstracts - more to come after presentations! Updates in bispecifics, MRD-guided therapy, CAR-T, and trispecifics. 👇

My Updated Myeloma Treatment Algorithms. #ASCO25 Bookmark! Presented at COMy. 1) Newly Diagnosed myeloma transplant ineligible.

Exercise is medicine. #ASCO25

#ASCO25 And another one! Journal of Clinical Oncology: 5-yr CARTITUDE-1 results for cilta-cel CAR-T. 97 pts, 6 prior #MMsm lines, treated 2018-2019. All likely would have died; instead, 1/3 alive & well 5 yrs out with no maintenance! 👏 Beginning of the end for #plateauenvy? (cc Nina Shah)

Active drugs in myeloma and mechanism of action #ASCO2025 edition Approved: Black font. Investigational: Blue font

Just out. Updated myeloma mSMART guidelines on prevention and management of bispecific antibody associated Toxicities. Yi Lin Mayo Myeloma #ASCO25 Comprehensive and covers CRS, neurotoxicity, infection prevention and more. Link: msmart.org/mm-treatment-g…

Just out: Myeloma mSMART recommendations for prevention and management of CAR-T related toxicities including CRS, neurotoxicity, cytopenias, and more. Yi Lin #ASCO25 Cilta-cel, Ide-cel msmart.org/mm-treatment-g…

Is this the end of rivaroxaban for acute VTE? Lana Castellucci presenting the COBBRA trial - 1st RCT comparing apixaban to riva over 3 months. 56% reduction in bleeding risk with apixaban. A safer Rx with the same efficacy. #ISTH2025

The paper of the day: a landmark publication that is bound to serve as a reference for years to come! ⁦NatureRevClinOncol⁩ ⁦Thanos Dimopoulos⁩ ⁦COMy⁩ ⁦IACH⁩ ⁦Meral Beksac⁩ ⁦

Looking forward to the series!

Excellently written Nature Medicine review, and honestly the best graphics re: CAR-T toxicities (inc. infections & SPMs) that I’ve ever seen 👏 these will be used in slide decks everywhere! Congrats Kai Rejeski Joshua Hill, MD Michael Jain and thanks for writing this! #MMsm #lymsm

Approach to newly diagnosed myeloma has become streamlined. Bookmark.

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab ashpublications.org/blood/article-…

Just out! Current Risk stratification of all Plasma Cell Disorders. MGUS, SMM, Myeloma, Amyloidosis. We paid Open Access fees so you can download and read freely! Lots of Tables. Bookmark. Saurabh Zanwar Shaji Kumar Leukemia Journal Link: nature.com/articles/s4137…

Great thread!